Zydus Lifesciences Q1 results: Net profit jumps 31% to Rs 1420 crore
Zydus Lifesciences reported a net profit jump of 31% to Rs 1420 crore in Q1FY25 led by robust sales growth in India and US markets.
The drug maker had reported a net profit of Rs 1,087 crore in the April-June quarter of last fiscal.
Revenue from operations grew 21% YoY to Rs 6208 crore.
On a quarter-on-quarter (QoQ) basis the net profit rose 20% and revenue by 12.2%.
The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 38.4% YoY to Rs 2084 crore. On QoQ, EBITDA increased 27.8%.
The EBITDA margins for Q1FY25 improved 430 basis points YoY to 33.6%.
The company has spent Rs. 301 crore on capex for the quarter, while research & development (R&D) investments stood at Rs. 392.5 crore or 6.3% of revenues.
India sales rose 15% YoY to Rs 2212 crore in Q1FY25. The formulation business gained 12% to Rs 1376 crore.
The branded formulation segment outpaced the market growth both in chronic and acute segments.
The company launched 10 new products including line extensions with 3 first-in-India launches, retaining leadership position in the nephrology segment while in oncology it remained the fastest growing Indian company.
The consumer wellness sales rose 21% to Rs 837 crore. India contributes 37% of overall sales.
US formulation business that constitutes 51% of revenue, rose 26% YoY to Rs 3093 crore driven by new product launches and volume expansion in the base portfolio.
The company launched 7 new products during the quarter. New launches for the quarter include launch of the second
